Skip to main content

Advertisement

SpringerLink
Log in

Is open innovation the way forward for big pharma?

  • Comment
  • Published:

From Nature Reviews Drug Discovery

View current issue Sign up to alerts

Abstract

The current, fully integrated business model of large pharmaceutical companies is increasingly considered to be unsustainable, and so new approaches that engage large and small companies, governments and academic institutions are needed. Could 'open innovation' models that have proved successful in other sectors be fruitfully adopted by the pharmaceutical industry?

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Chesborough, H. W. Open Innovation: the New Imperative for Creating and Profiting from Technology 1–272 (Harvard Business School, Boston, Masschusetts, 2003).

    Google Scholar 

  2. Tapscott, D. & Williams, A. D. Wikinomics: How Mass Collaboration Changes Everything 1–320 (Portfolio, New York, 2006).

    Google Scholar 

  3. Munos, B. Can open-source R&D reinvigorate drug research? Nature Rev. Drug Discov. 5, 723–729 (2006).

    Article  CAS  Google Scholar 

  4. Huston, L. & Sakkab, N. Connect and Develop: Inside Procter & Gamble's new model for innovation. Harv. Bus. Rev. 84, 58–66 (2006).

    Google Scholar 

  5. Barnes, M. R. et al. Lowering industry firewalls: pre-competitive informatics initiatives in drug discovery. Nature Rev. Drug Discov. 8, 701–708 (2009).

    Article  CAS  Google Scholar 

  6. Hughes, B. Harnessing open innovation. Nature Rev. Drug Discov. 8, 344–345 (2009).

    Article  Google Scholar 

  7. Alexy, O. et al. Does IP strategy have to cripple open innovation?' MIT Sloane Management Rev. 51, 73–77 (2009).

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Jackie Hunter is Senior Vice President of Science Environment Development at GlaxoSmithKline, Stevenage, Hertfordshire SG1 2NY, UK.,

    Jackie Hunter

  2. Susie Stephens is Director of Biomedical Informatics at Johnson & Johnson Pharmaceutical Research & Development, 145 King of Prussia Road, Radnor, Pennsylvania 19087, USA. The views expressed herein are not necessarily those of the employer of S.S.,

    Susie Stephens

Authors
  1. Jackie Hunter
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Susie Stephens
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jackie Hunter.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hunter, J., Stephens, S. Is open innovation the way forward for big pharma?. Nat Rev Drug Discov 9, 87–88 (2010). https://doi.org/10.1038/nrd3099

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd3099

  • Springer Nature Limited

This article is cited by

Search

Navigation